SBI MNC Fund
The scheme seeks to provide the investor with the opportunity of long-term capital appreciation by investing in diversified portfolio comprising primarily of MNC companies.
Growthvine rating: 2/5 — ranked #98 of 184 in category.
Fund basics
| Category | Equity: Thematic |
|---|
| NAV | ₹396.65 (as of 2026-10-01) |
|---|
| AUM | ₹6,718 Cr |
|---|
| Expense ratio | 1.55% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Tanmaya Desai |
|---|
| Exit load | 1% for redemption within 30 days |
|---|
Performance & risk
| 5-year annualised return | 7.18% |
|---|
| Sharpe ratio | 0.23 |
|---|
| Standard deviation | 13.58% |
|---|
| Max drawdown | −74.20% |
|---|
| Alpha | -2.13 |
|---|
| Beta | 0.76 |
|---|
Over 5 years, captured 30.1% of NIFTY CPSE's upside and 28.7% of its downside.
Market cap allocation
| Large cap | 40.7% |
|---|
| Mid cap | 26.5% |
|---|
| Small cap | 32.9% |
|---|
Concentration
| Top 5 holdings | 21.7% |
|---|
| Top 10 holdings | 38.5% |
|---|
| Total holdings | 45 |
|---|
Top holdings
- Divis Laboratories Ltd. — 5.6%
- Cummins India Ltd. — 4.6%
- Bosch Ltd — 4.0%
- Vedanta Aluminium Metal Limited — 3.9%
- Sona BLW Precision Forgings Limited — 3.6%
- Navin Fluorine International Limited — 3.6%
- Sun Pharmaceutical Industries Ltd. — 3.5%
- Aether Industries Limited — 3.3%
- ABB India Limited — 3.2%
- Anthem Biosciences Limited — 3.1%
Top sectors
- Automobile — 22.4%
- Pharma & Biotech — 22.1%
- Chemicals — 11.1%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 12.3% | Q1 (Top) | #15 of 167 |
| 2025 | −5.6% | Q4 (Bottom) | #120 of 132 |
| 2024 | 8.2% | Q4 (Bottom) | #84 of 86 |
| 2023 | 23.5% | Q4 (Bottom) | #56 of 66 |
| 2022 | −5.7% | Q4 (Bottom) | #47 of 55 |